BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36045304)

  • 1. Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
    Adams AM; Carpenter EL; Clifton GT; Vreeland TJ; Chick RC; O'Shea AE; McCarthy PM; Kemp Bohan PM; Hickerson AT; Valdera FA; Tiwari A; Hale DF; Hyngstrom JR; Berger AC; Jakub JW; Sussman JJ; Shaheen MF; Yu X; Wagner TE; Faries MB; Peoples GE
    Cancer Immunol Immunother; 2023 Mar; 72(3):697-705. PubMed ID: 36045304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
    Carpenter EL; Van Decar S; Adams AM; O'Shea AE; McCarthy P; Chick RC; Clifton GT; Vreeland T; Valdera FA; Tiwari A; Hale D; Kemp Bohan P; Hickerson A; Smolinsky T; Thomas K; Cindass J; Hyngstrom J; Berger AC; Jakub J; Sussman JJ; Shaheen MF; Yu X; Wagner TE; Faries M; Peoples GE
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
    Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
    Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
    Vreeland TJ; Clifton GT; Hale DF; Chick RC; Hickerson AT; Cindass JL; Adams AM; Bohan PMK; Andtbacka RHI; Berger AC; Jakub JW; Sussman JJ; Terando AM; Wagner T; Peoples GE; Faries MB
    Ann Surg Oncol; 2021 Oct; 28(11):6126-6137. PubMed ID: 33641012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
    Adams AM; Chick RC; Vreeland TJ; Clifton GT; Hale DF; McCarthy PM; O'Shea AE; Bohan PMK; Hickerson AT; Park H; Sloan AJ; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Wagner T; Faries MB; Peoples GE
    Melanoma Res; 2021 Aug; 31(4):378-388. PubMed ID: 34193804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.
    Hardin MO; Vreeland TJ; Clifton GT; Hale DF; Herbert GS; Greene JM; Jackson DO; Berry JE; Nichols P; Yin S; Yu X; Wagner TE; Peoples GE
    Immunotherapy; 2018 Apr; 10(5):373-382. PubMed ID: 29473470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
    Herbert GS; Vreeland TJ; Clifton GT; Greene JM; Jackson DO; Hardin MO; Hale DF; Berry JS; Nichol P; Yin S; Yu X; Wagner TE; Peoples GE
    Vaccine; 2018 May; 36(23):3247-3253. PubMed ID: 29724512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
    Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
    Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
    Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
    Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor.
    Zhang Y; Liu X; Wang R; Liu S; Wang Y; Jing L; Louis MDJ; Cao R
    Biomed Pharmacother; 2018 Jan; 97():784-792. PubMed ID: 29112931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.
    von Euw EM; Barrio MM; Furman D; Levy EM; Bianchini M; Peguillet I; Lantz O; Vellice A; Kohan A; Chacón M; Yee C; Wainstok R; Mordoh J
    J Transl Med; 2008 Jan; 6():6. PubMed ID: 18221542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
    Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
    J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
    de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
    J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
    Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ
    J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.
    Dillman RO; Nistor GI; Keirstead HS
    Hum Vaccin Immunother; 2023 Dec; 19(1):2198467. PubMed ID: 37133853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.